(Circulation. 1996;93:18-22.)
© 1996 American Heart Association, Inc.
Articles |
From the Departments of Pharmacology (T.M., F.V.), Cardiology (C.B., J.-L.A., M.H., E.v.B., J.-M.L., M.E.B.), and Anesthesiology (B.V.), University of Lille (France).
Correspondence to Christophe Bauters, MD, Service de Cardiologie B et Hémodynamique, Blvd du Prof J. Leclercq, 59037 Lille Cedex, France.
Background After experimental angioplasty, partial or complete reendothelialization of the denuded surface occurs; the function of the regenerated endothelium has, however, been shown to be abnormal. Basic fibroblast growth factor (bFGF) is mitogenic for endothelial cells in vitro and in vivo. We investigated whether chronic administration of bFGF in a rabbit model of balloon denudation might not only improve endothelial regrowth but also restore normal physiological responses to endothelium-dependent agonists.
Methods and Results Thirty-nine New Zealand White rabbits underwent balloon denudation of the right iliac artery. Twenty rabbits received intravenous administration of bFGF (2.5 µg twice a week for 2 weeks). Nineteen rabbits receiving saline injections served as controls. Animals were killed on day 28 for assessment of reendothelialization and neointimal thickening and for analysis of in vitro vasoreactivity. Animals in the bFGF group had a significantly (P<.005) greater degree of reendothelialization than controls (115±13 versus 55±6 mm2). Neointimal thickening was similar in the two groups. Four weeks after denudation, endothelium-independent responses did not differ significantly between the two groups. In contrast, the maximal endothelium-dependent acetylcholine-induced relaxation of the bFGF-treated animals (Emax, 40±7%) was significantly greater than that of the control group (Emax, 11±9%; P<.05).
Conclusions Systemic administration of bFGF restores, in large part, the responses of previously denuded arterial segments to endothelium-dependent vasodilators. Angiogenic growth factors may help to reestablish normal endothelial cell function in patients who have undergone angioplasty.
Key Words: endothelium angioplasty growth substances vasodilation
This article has been cited by other articles:
![]() |
W. Scharbrodt, C. R. W. Kuhlmann, Y. Wu, C. A. Schaefer, A. K. Most, U. Backenkohler, T. Neumann, H. Tillmanns, B. Waldecker, A. Erdogan, et al. Basic Fibroblast Growth Factor-Induced Endothelial Proliferation and NO Synthesis Involves Inward Rectifier K+ Current Arterioscler Thromb Vasc Biol, July 1, 2004; 24(7): 1229 - 1233. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Walter, K. Rittig, F. H. Bahlmann, R. Kirchmair, M. Silver, T. Murayama, H. Nishimura, D. W. Losordo, T. Asahara, and J. M. Isner Statin Therapy Accelerates Reendothelialization: A Novel Effect Involving Mobilization and Incorporation of Bone Marrow-Derived Endothelial Progenitor Cells Circulation, June 25, 2002; 105(25): 3017 - 3024. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Corseaux, T. Meurice, I. Six, L. Rugeri, M. D. Ezekowitz, P. Rouvier, R. Bordet, C. Bauters, and B. Jude Basic Fibroblast Growth Factor Increases Tissue Factor Expression in Circulating Monocytes and in Vascular Wall Circulation, April 25, 2000; 101(16): 2000 - 2006. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. A. Caramori, V. C. Lima, P. H. Seidelin, G. E. Newton, J. D. Parker, and A. G. Adelman Long-term endothelial dysfunction after coronary artery stenting J. Am. Coll. Cardiol., November 15, 1999; 34(6): 1675 - 1679. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. Flanagan, T. Aoyagi, L. W. Arnold, C. Maute, A. M. Fujii, J. Currier, D. Bergau, H. B. Warren, and K. Rakusan Effects of Chronic Heparin Administration on Coronary Vascular Adaptation to Hypertension and Ventricular Hypertrophy in Sheep Circulation, August 31, 1999; 100(9): 981 - 987. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Chen, T. Asahara, K. Krasinski, B. Witzenbichler, J. Yang, M. Magner, M. Kearney, W. A. Frazier, J. M. Isner, and V. Andres Antibody Blockade of Thrombospondin Accelerates Reendothelialization and Reduces Neointima Formation in Balloon-Injured Rat Carotid Artery Circulation, August 24, 1999; 100(8): 849 - 854. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Six, E. Van Belle, R. Bordet, D. Corseaux, J. Callebert, B. Dupuis, C. Bauters, and M. E. Bertrand L-Arginine and L-NAME have no effects on the reendothelialization process after arterial balloon injury Cardiovasc Res, August 15, 1999; 43(3): 731 - 738. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Van Belle, C. Bauters, T. Asahara, and J. M. Isner Endothelial regrowth after arterial injury: from vascular repair to therapeutics Cardiovasc Res, April 1, 1998; 38(1): 54 - 68. [Full Text] [PDF] |
||||
![]() |
A VARNAVA Coronary artery remodelling Heart, February 1, 1998; 79(2): 109 - 110. [Full Text] |
||||
![]() |
F. Wempe, V. Lindner, and H. G. Augustin Basic Fibroblast Growth Factor (bFGF) Regulates the Expression of the CC Chemokine Monocyte Chemoattractant Protein-1 (MCP-1) in Autocrine-Activated Endothelial Cells Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 2471 - 2478. [Abstract] [Full Text] |
||||
![]() |
E. Van Belle, A. Rivard, D. Chen, M. Silver, S. Bunting, N. Ferrara, J. F. Symes, C. Bauters, and J. M. Isner Hypercholesterolemia Attenuates Angiogenesis but Does Not Preclude Augmentation by Angiogenic Cytokines Circulation, October 21, 1997; 96(8): 2667 - 2674. [Abstract] [Full Text] |
||||
![]() |
D. S. Winlaw Angiogenesis in the Pathobiology and Treatment of Vascular and Malignant Diseases Ann. Thorac. Surg., October 1, 1997; 64(4): 1204 - 1211. [Abstract] [Full Text] |
||||
![]() |
C. R. White, J. Shelton, S.-J. Chen, V. Darley-Usmar, L. Allen, C. Nabors, P. W. Sanders, Y.-F. Chen, and S. Oparil Estrogen Restores Endothelial Cell Function in an Experimental Model of Vascular Injury Circulation, September 2, 1997; 96(5): 1624 - 1630. [Abstract] [Full Text] |
||||
![]() |
E. Van Belle, F. O. Tio, T. Couffinhal, L. Maillard, J. Passeri, and J. M. Isner Stent Endothelialization: Time Course, Impact of Local Catheter Delivery, Feasibility of Recombinant Protein Administration, and Response to Cytokine Expedition Circulation, January 21, 1997; 95(2): 438 - 448. [Abstract] [Full Text] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1996 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |